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Predicting renal outcomes in severe lupus nephrltls: Contributions of
clinical and histologic data. Despite several years of intense investiga-
tion, there continues to be controversy about the value of clinical,
demographic and histologic features in prediction of outcomes of lupus
nephritis. In addition, contemporary treatments have reduced the risk
of progressive renal injury and thus may have altered the prognostic
significance of some of these factors. We have therefore re-examined
the predictive value of variables previously associated with an in-
creased risk of renal insufficiency by studying 65 patients with severe
lupus nephritis treated with intensive regimens of intravenous pulse
cyclophosphamide or methyiprednisolone. Five clinical features at
study entry were each associated with an increased probability of
doubling the serum creatinine: age greater than 30 years, Black race,
hematocrit less than 26%, serum creatinine greater than 2.4 mgldl, and
C3 complement less than 76 mg/dl. By multivariate survival analysis,
serum creatinine, hematocrit and race emerged as the strongest set of
independent clinical predictors; the other clinical and demographic
factors, including age and C3 complement did not contribute signifi-
cantly to Outcome predictions in the context of these three variables.
Renal biopsy evaluation offered additional prognostic information and
showed that patients with severe active and chronic histologic changes
were at increased risk for developing renal insufficiency. The combina-
tion of cellular crescents and interstitial fibrosis was particularly omi-
nous. Outcome predictions based on the strongest clinical model (serum
creatinine, hematocrit and race) were significantly enhanced by the
addition of renal pathology data. Consideration of these prognostic
factors may contribute to decisions regarding the type and intensity of
immunosuppressive therapy for patients with lupus nephritis.
The varied and unpredictable nature of lupus nephritis and
the risks associated with its treatment have challenged investi-
gators to refine the estimates of prognosis and to develop
rational approaches to therapy. Several studies have under-
scored the predictive value of demographic, clinical and labo-
ratory data prior to treatment [1—6].
Since the introduction of percutaneous renal biopsy into
clinical practice four decades ago, it has been considered that
detailed morphologic studies could offer a more direct estimate
of the type and severity of lupus kidney disease and provide
further rationale for therapeutic decisions. To record and ana-
lyze the diverse histologic changes observed in these patients,
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investigators have employed several potentially complementary
techniques including renal biopsy classification [7—14], and
semi-quantitative scoring of specific glomerular, tubular, inter-
stitial, and vascular changes depicting the severity of active and
of chronic, irreversible pathologic lesions [8, 15—35]. Such
information has been useful in estimating the risk of progressive
renal failure and death [8, 9, 11—14, 20, 22, 23, 25—28, 30-37].
For example, we found a decade ago that patients with diffuse
proliferative glomerulonephritis who manifested severe active
or marked chronic renal parenchymal injury had a 40% proba-
bility of end-stage kidney disease after five years of observation
[38]. The prognostic significance of irreversible histologic
change in patients with active nephritis was demonstrated by
multivariate analysis [39], and several other groups have de-
scribed a significant impact of kidney scarring on renal function
and patient survival outcomes [20, 22, 25, 27, 28, 30—32, 34—37].
Nonetheless, there continues to be controversy about the
predictive value of clinical and histologic features of this
disorder [1, 5, 6, 10, 13, 40, 41]. Varied conclusions may relate
to differences in patient selection criteria, prognostic factors
and outcome measures that were studied. Furthermore, thera-
peutic intervention alters the natural history of this disease.
Contemporary treatments reduce the risk of progressive renal
injury [42] and may alter the prognostic significance of severe
active and chronic histologic change observed when therapy is
initiated. Further study is needed to better define the factors
that presently influence the outcome of this disorder.
Toward this end, we have re-examined the predictive value of
variables previously associated with an increased risk of renal
insufficiency by studying a group of patients with severe lupus
nepbritis treated over the past decade with aggressive induction
regimens of pulse intravenous cyclophosphamide or methyl-
prednisolone [43]. We explored the following questions: (1)
what clinical and morphologic attributes at the initiation of
therapy were associated with an increased probability of renal
insufficiency? (2) Do histologic data significantly enhance pre-
dictions of time to doubling serum creatinine based on the
strongest set of clinical predictors observed in this study? We
found that several clinical and histologic features contribute
independently to predictions of doubling serum creatinine.
Recognition of these prognostic factors may contribute to the
formulation of therapeutic recommendations for patients with
lupus nephritis.
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Methods
Patients
Patients included in the present analysis had four or more
criteria for the diagnosis of systemic lupus erythematosus
(SLE) [44] and severe lupus nephritis. Severe lupus nephritis
was defined by a nephritic urine sediment and impaired renal
function [creatinine clearance 80 ml/minll .73 m2 body surface
area (BSA)]. If the creatinine clearance was >80 mlIminIl .73 m
BSA, the renal biopsy within six weeks of study entry had to
show severely active histology with epithelial crescents and/or
fibrinoid necrosis in more than 25% of glomeruli. Patients were
excluded if they were pregnant or nursing or had: (1) a creati-
nine clearance <25 mI/mm/i .73 m2 BSA for more than three
months prior to study entry, (2) received cytotoxic drug therapy
for more than 10 weeks at any time in the past, (3) active
infection, (4) insulin-dependent diabetes mellitus, or (5) previ-
ous malignancy.
Treatment regimens
Between 1981 and 1986, 65 patients were randomized to
receive: (1) pulse intravenous infusions of methylprednisolone
(1.0 g/m2 BSA) monthly for six months, (25 patients), (2) single
monthly intravenous doses of cyclophosphamide (0.5 to 1.0
g/m2 BSA) for six months (20 patients), or (3) monthly intrave-
nous infusions of cyclophosphamide for six months followed by
quarterly doses for an additional two years (20 patients).
Patients also received prednisone 0.5 mg/kg per day for four
weeks; then prednisone was tapered each week by 5 mg every
other day to the minimum dose required to control extrarenal
disease activity (but not less than the target dose of 0.25 mg/kg
every other day). Details of the therapeutic regimen have been
described previously [43]. Patients were evaluated at least
every three months for the first 30 months and at least every six
months thereafter at the NIH Clinical Center. The closing date
for this analysis was June 1991. No patients were lost to
follow-up. The mean (± standard error) interval of observation
for patients not progressing to renal insufficiency was 59.4 (4.8)
months.
Renal biopsy
Lupus nephritis was classified by World Health Organization
(WHO) criteria [45], and specific histologic features (glomerular
cell proliferation, leukocyte exudation in glomeruli, karyorrhex-
is and fibrinoid necrosis, cellular crescents, hyaline deposits,
interstitial inflammation, glomerular sclerosis, fibrous cres-
cents, tubular atrophy and interstitial fibrosis) were semiquan-
titatively graded (0 to 3+, indicating none, mild, moderate, or
severe) as described previously [38]. The sum of the scores for
individual active lesions (activity index) and chronic, irrevers-
ible lesions (chronicity index) were calculated. Fibrinoid necro-
sis and cellular crescents were each arbitrarily weighted by a
factor of two [22].
Outcome measures
The primary study outcome was renal insufficiency defined as
sustained doubling (for more than a month) of serum creatinine
over the lowest value that had been reached during the study
period. The following clinical and histologic features at study
entry were analyzed for predictive value: age, sex, race,
duration of SLE, duration of lupus nephritis, hypertension
(requirement for medication to maintain diastolic 90 mm Hg),
serum creatinine, albumin, cholesterol, 24-hour urine protein
excretion, hematocrit, C3 complement, antibodies to native
DNA (Farr assay, normal <25%), WHO renal pathology clas-
sification, specific histologic features listed above, as well as the
composite activity and chronicity indices.
Statistical analyses
Since the duration of patient follow-up was not uniform,
statistical methods appropriate for the analysis of censored data
were employed [46—48]. Clinical and histologic variables were
individually tested for prognostic significance by cumulative
survival analysis using time from study entry to renal insuffi-
ciency as the measure of outcome. For the analysis of contin-
uous variables, groups of patients were formed by dividing the
range of the variable at various cut-points and combining
contiguous groups that had similar probabilities of renal insuf-
ficiency. The cumulative survival curves were derived by the
Kaplan-Meier method [49]; thus, the estimate of survival prob-
ability was re-calculated at each unique time of renal insuffi-
ciency. The equality of survival curves obtained for different
subgroups of patients was assessed by the Mantel-Haenszel test
[50, 51]. Two-tailed tests were used to estimate P values
throughout.
Prognostic factors were entered into equations which relate
the factors, as in multiple regression, to the outcome—ex-
pressed as the natural logarithm of survival time [52, 53]. The
equation, referred to as a statistical model, allows inferences
about one prognostic factor adjusted for variation in the others.
Variables were added and removed from the equation in a
stepwise manner (P to enter < 0.1; P to remain < 0.05) to
evaluate their ability to enhance the prediction of renal insuffi-
ciency. The various models were compared by the likelihood
ratio test to determine the impact of adding or removing a factor
from the equation. Thus, for example, we could determine the
impact on outcome predictions of adding renal histologic data to
a model containing the strongest clinical prognostic factors.
Results
Patient characteristics at study entry
Clinical and histologic features of lupus nephritis were exam-
ined in an attempt to identify early prognostic indicators of
renal function outcome. There were 65 subjects (60 female and
5 male); 22 developed renal insufficiency [defined as sustained
doubling (for more than a month) of serum creatinine over the
lowest value that had been reached during the study period]. On
average (± SE), at study entry, the patients were 29.6 (1.0)
years of age, had SLE for 45.4 (6.0) months, had recognized
renal involvement for 23.7 (4.3) months, and had an elevated
serum creatinine of 1.85 (0.12) mg/dl. The racial origins were as
follows: 30 Caucasian, 28 Black, 4 Oriental, and 3 Hispanic.
Renal biopsy specimens adequate for detailed light micro-
scopic examination were obtained within six weeks of study
entry from 64 patients and showed: 56 diffuse proliferative, 5
focal proliferative, and 3 mixed membranous and focal prolif-
erative glomerulonephritis. The mean activity index was 9.4
(0.5), and the mean chronicity index was 3.8 (0.3).
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Probability
Variable
Number
of patients
of not
doubling
creatinine
at 5 years
(±SE)a
P
valueb
Age years
30 38 0.79 (0.07) 0.02 1
>30 27 0.48 (0.1)
Sex
Female 60 0.66 (0.07) 0.923
Male 0.60 (0.22)
Race
Black 28 0.49 (0.11) 0.007
Others 37 0.76 (0.08)
Duration of SLE months
 30 32 0.67 (0.09) 0.777
>30 32 0.63 (0.1)
Duration of SLE nephritis months
 24 45 0.70 (0.07) 0.167
>24 19 0.51 (0.13)
Hematocrit %
<26 16 0.26 (0.12) 0.0009
26 49 0.78 (0,06)
Serum creatinine mg/dl
2.4 49 0.79 (0.06) 0.0003
> 2.4 16 0.31 (0.12)
Serum albumin gidI
2.5 30 0.57 (0.1) 0.241
> 2.5 35 0.73 (0.08)
Serum cholesterol mg/dl
 300 O.M (0.09) 0.79
>300 32 0.67 (0.09)
24-Hour urinary protein g
 7,0 48 0.71 (0.07) 0.181
> 7.0 17 0.52 (0.12)
C3 complement mg/dl
<76 37 0.52 (0.09) 0.023
 76 28 0.84 (0.07)
DNA binding °'80 39 0.72 (0.08) 0.284
>80 24 0.56 (0.11)
Hypertension
Absent 18 0.68 (0.12) 0.607
Present 47 0.68 (0.07)
Treatmente
i.v. Methylprednisolone 25 0.50 (0.10) 0,110
i.v. Cyclophosphamide 40 0.77 (0.07)
The estimated probabilities of not doubling serum creatinine at 5
years (±sE) are shown for illustrative purposes. Statistical analyses
were performed according to footnote b.
b Significance level for the Mantel-Haenszel test that evaluates the
equality of the survival curves which were obtained for subgroups of
patients defined by level of the prognostic variable.
C Shows the comparison of renal function outcomes for all patients
randomized to either regimen of i.v. cyclophosphamide vs. methyipred-
nisolone. Details of the analysis of therapeutic outcomes are reported in
[43].
Analysis of renal insufficiency outcomes
To study the predictive value of clinical features at study
entry, cumulative survival curves were derived for each vari-
able shown in Table 1, and the survival curves were compared
as described in the Methods section. The results underscore the
prognostic significance of five univariate clinical predictors:
age, race, serum creatinine, hematocrit, and C3 complement
2::1:
P=0.00090—
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Fig. 1. Cumulative survival curves demonstrating the prognostic im-
pact of (A) serum creatinine >2.4 mgldl, and (B) hematocrit <26% at
study entry on the probability of not doubling serum creatinine.
Equality of survival curves was assessed by Mantel-Haenszel test.
Numbers on the curves indicate the number of patients in the group that
remains at risk.
levels. Age greater than 30 years, Black race, hematocrit less
than 26%, serum creatinine greater than 2.4 mgldl, and C3
complement less than 76 mg/dl were each individually associ-
ated with an increased probability of renal insufficiency. The
survival curves based on two univariate predictors (serum
creatinine and hematocnt) are illustrated in Figure 1.
To determine which of the clinical factors in Table 1 were
independent predictors of renal insufficiency, multivariate sur-
vival analyses were performed. The strongest combination of
clinical predictors was serum creatinine, hematocrit and race
(Table 3, first model). In the context of these variables, the
other clinical factors did not contribute statistically to the model
and did not significantly enhance outcome predictions of the
model.
Renal insufficiency developed in 19 of 56 patients with diffuse
proliferative glomerulonephritis, in one of five patients with
focal proliferative glomerulonephritis, and in two of three
Table 1. Prognostic significance of clinical variables at study entry A
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Probability
of not
doubling
creatinine
Variable
Number of
patients
at 5 years
(±SE)a P valu&'
Glomerular cell proliferation
Mild/moderate 48 0.65 (0.07) 0.799
Severe 16 0.65 (0.13)
Fibrinoid necrosis, karyorrhexis
Absent 16 0.78 (0.11) 0.325
Present 48 0.61 (0.08)
Cellular crescents
None/mild 44 0.74 (0.07) 0.046
Moderate/severe 20 0.46 (0.12)
Hyaline deposits
Absent 26 0.72 (0.09) 0.389
Present 38 0.60 (0.09)
Leukocyte exudation
Absent 27 0.67 (0.1) 0.740
Present 37 0.63 (0.09)
Interstitial inflammation
None/mild 45 0.72 (0.07) 0.057
Moderate/severe 19 0.50 (0.12)
Glomerular sclerosis
Absent 29 0.73 (0.09) 0.307
Present 35 0.58 (0.09)
Fibrous crescents
Absent 40 0.64 (0.08) 0.892
Present 24 0.67 (0.1)
Tubular atrophy
None/mild 48 0.71 (0.07) 0.082
Moderate/severe 16 0.50 (0.13)
Interstitial fibrosis
None/mild 36 0.76 (0.08) 0.050
Moderate/severe 28 0.51 (0.1)
Activity Index
Low 20 0.84 (0.09) 0.061
Mid/high 44 0.55 (0.08)
Chronicity Index
Low/mid 32 0.75 (0.08) 0.072
High 32 0.55 (0.09)
a The estimated probabilities of not doubling serum creatinine at 5
years (±sa) are shown for illustrative purposes. Statistical analyses
were performed according to footnote b.b Significance level for the Mantel-Haenszel test that evaluates the
equality of the survival curves which were obtained for subgroups of
patients defined by level of the prognostic variable.
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Fig. 2. Cumulative survival curves demonstrating the prognostic im-
pact of renal pathology data at study entry on the probability of not
doubling serum creatinine. A. The high-risk group consists of patients
whose renal biopsy showed both Al >7 and CI >3. Other indicates
individuals whose renal biopsy lacked this combination of histologic
features. B. The high-risk group consists of patients whose renal biopsy
showed both cellular crescents and moderate to severe interstitial
fibrosis (CC + IF). Other indicates individuals whose renal biopsy
lacked this combination of histologic features. Equality of survival
curves was assessed by Mantel-Haenszel test. Numbers on the curves
indicate number of patients in the group that remains at risk.
insufficiency. By multivariate survival analysis, cellular cres-
cents and interstitial fibrosis emerged as the strongest combi-
nation of histologic prognostic factors (details not included). As
shown in Figure 2, the combination of cellular crescents and
moderate to severe interstitial fibrosis (CC + IF) was associated
with a particularly high probability of doubling serum creati-
nine.
To address the controversial issue of whether evaluation of
renal pathology significantly improves outcome predictions in
patients with lupus nephritis, the histologic combination CC +
IF was added to the statistical model (Table 3) containing the
strongest set of clinical prognostic features (serum creatinine,
hematocrit and race). The comparison statistic indicates that
Table 2. Prognostic significance of renal biopsy variables A
100 40
0
00.)
CO C)
'- .0
0
00.)cc
CO C)c
0
80
60
40
20
0
B
100
80
60
40
20
80
patients with mixed membranous and proliferative nephropa-
thy. To obtain additional prognostic information from renal
morphology, cumulative survival curves were derived for indi-
vidual histologic features and for the composite activity (Al)
and chronicity (CI) indices by level. The survival curves were
compared statistically as shown in Table 2.
By univariate analysis, patients with moderate to severe
elevations of the activity index (Al >7) or of the chronicity
index (CI >3) tended to be at increased risk of renal insuffi-
ciency. The combination of Al >7 and CI >3 was associated
with a marked increased probability of doubling serum creati-
nine (Fig. 2).
The predictive value of each specific morphologic attribute
was evaluated as well. By univariate analysis, cellular cres-
cents, interstitial inflammation, interstitial fibrosis, and tubular
atrophy identified patients at modestly increased risk of renal
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Table 3. Comparison of statistical models that predict time to renal insufficiency using various combinations of variables
Prognostic factorsa
Serum Pathology
Survival model creatinine Hematocrit Race variable Compariso&'
1. Clinical predictors
Coefficientc —1.514 1.205 —1.341
Standardized coefficientd —3.319 2.613 —3.049
P valuee 0.001 0.012 0.002
2. Clinical and pathologic predictors 0.029
Coefficient —1.227 1.179 —1.276 —0.986
Standardized coefficient —2.566 2.575 —2.927 —2.180
P value 0.01 0.013 0.003 0.029
a Clinical variables are categorized as shown in Table I. Pathology variable (CC + IF) is categorized as shown in Figure 2.
b Pvalue of the likelihood ratio test that compares the outcome predictions of the two models. This tests the impact of adding renal pathology
information to the clinical model.
The estimated regression coefficients in the exponential survival model; a negative coefficient indicates a negative effect on survival time in this
model (531.
d The standardized coefficient is the estimated coefficient divided by its estimated standard error. Values outside the range (—1.96, +1.96) show
that the variable contributes significantly (P < 0.05) to the model's ability to estimate failure probabilities.
P value of the likelihood ratio test that evaluates the impact on outcome predictions of eliminating each variable from the model, Prognostic
factors that significantly (P < 0.05) enhance the prediction of renal insufficiency remain in the model.
the predictions of the clinical model were significantly enhanced
by the addition of renal biopsy data (P = 0.029).
Discussion
The present study examines the prognostic impact of various
clinical and histologic variables in patients with severe lupus
nephritis treated with intravenous methyiprednisolone or cyclo-
phosphamide. Five clinical features at study entry were each
associated with an increased probability of renal insufficiency:
age greater than 30 years, Black race, hematocrit less than 26%,
serum creatinine greater than 2.4 md/dl, and C3 complement
less than 76 mg/dl. By multivariate survival analysis, the
strongest clinical predictive model was composed of serum
creatinine, hematocrit and race. In the context of these three
variables, no other clinical factor contributed significantly to
predictions of renal function outcome. Thus, serum creatinine,
hematocrit and race contained prognostic information that
incorporated and superseded that of the other clinical variables
including age and C3 complement.
To determine whether renal histologic data were also redun-
dant in the context of these strong clinical predictors (serum
creatinine, hematocrit and race), pathology information was
added to the clinical model (Table 3) in the form of a variable
(CC + IF) that indicated the presence or absence of cellular
crescents and moderate to severe interstitial fibrosis at study
entry. The predictions of the strongest clinical model (contain-
ing serum creatinine, hematocrit and race) were significantly
enhanced by the addition of renal biopsy observations.
The ominous coalition of histologic features (CC + IF) that
contributed to the clinical and pathologic model above (Table 3)
was similar to the composite of morphologic attributes (cellular
crescents, glomerular sclerosis, and tubular atrophy) that iden-
tified particularly high risk patients in a previous study of
diffuse proliferative lupus nephritis [38]. The combination of
moderate to severe active and chronic irreversible renal paren-
chymal injury (Fig. 2) in this study was more predictive of renal
insufficiency than either feature considered separately (Table
2). It was impossible to determine whether the chronicity index
(CI) had a graded impact on prognosis in this study because so
few patients had a low CI. Different from our previous analyses
of lupus nephritis [38, 39], only two patients in this study had CI
equal to 0 and only 5 had CI equal to 1. The comparison of mid-
and high-range CI noted a decade ago in another study of lupus
nephritis [38] was comparable to observations in this report.
The current study confirms previous reports that an elevated
creatinine prior to treatment identifies patients at increased risk
for renal insufficiency or death [4—6, 25, 30—32, 34, 37, 39]. The
estimate of prognosis may be enhanced by consideration of
additional features that indicate the reversibility of the renal
dysfunction, including the duration of nephritis [5], the rate of
change of serum creatinine [21, and the renal histology. Kidney
biopsy evaluation offered a relatively direct appraisal of the
type of disorder involved and contributed significantly to pre-
dictions of renal outcome in this and other studies.
Alterations in serological parameters have been correlated
with histologic activity in patients with lupus nephritis [24, 54,
55]. In this analysis, C3 complement emerged as a potentially
important clinical prognostic factor (Table 1). However, in the
context of other clinical indications of severe SLE (such as
azotemia and anemia), the contribution of this variable to
outcome predictions diminished. Serologic abnormalities at
study entry may be transitory; observations over an extended
period of time may provide additional prognostic information
[35, 55—57].
Demographic factors such as age, sex and race have emerged
as important prognostic indicators in some [3, 25, 31, 32, 39,
581, but not all [28, 36, 59, 60], previous studies. We observed
that race and age were each predictors of renal function
outcome (Table 1). By niultivariate analysis, race contributed to
predictions of time to doubling serum creatinine even after
clinical and histologic features of severe active lupus nephritis
had entered the statistical model (Table 3).
The present study confirms and extends previous observa-
tions regarding the prognostic importance of renal histologic
evaluation in patients with lupus nephntis. By multivariate
analysis many [25, 30—32, 391, but not all [1, 5, 6], investigators
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have shown that kidney biopsy data enhance predictions of
short-term and long-term outcomes based on the strongest set
of clinical prognostic factors reported in that population. In the
current study, it was the combination of severe active and
chronic irreversible renal parenchymal injury that identified
particularly high-risk patients (Fig. 2). The prognostic impact of
this coalescence of adverse histologic features was demonstra-
ble employing the activity and chronicity indices. Several
elements of these composite scores appear to contribute little to
the estimate of prognosis (Table 2), in part probably reflecting
the favorable effect of therapy on active nephritis. Thus, we
sought to evaluate the strongest set of histologic predictors in
this study population. This analysis differs from our previous
approach [39] and that of the Lupus Nephritis Collaborative
Study Group [6, 41] which focused on the prognostic signifi-
cance of the composite activity and chronicity indices. In the
present study, the combination of cellular crescents and mod-
erate to severe interstitial fibrosis (CC + IF) identified patients
at particularly high-risk for doubling serum creatinine. Renal
pathology data (CC + IF) significantly enhanced outcome
predictions based on the strongest combination of clinical
prognostic factors.
Considerations regarding the natural history and treatment of
lupus nephritis remain enigmatic despite decades of intensive
investigation at many centers around the world. Clearly, many
factors impact on the prognosis of this highly pleomorphic
disorder, and controversy has emerged because of the diversity
of predictors identified in various clinical studies. This variabil-
ity may reflect differences in patient selection criteria, as well as
the prognostic factors and outcome measures that were evalu-
ated. For example, the effect of varying patient selection
criteria has been observed in our own studies as described
above. Furthermore, these are not studies of the natural history
of this disease; immunosuppressive treatments are widely used
in an effort to change the course of lupus nephritis. Conse-
quently, we are studying the predictive value of clinical and
histologic factors in the context of various therapies that have
very likely altered the prognostic impact of the variables. As
more patients with severe lupus nephritis are treated with
intravenous pulse regimens of immunosuppression, it is impor-
tant that we update our assessment of the prognosis of this
disease. This information may contribute to the evaluation of
the potential benefits and risks of intensive immunosuppressive
therapy for patients with various types of lupus nephritis.
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